pyrazines has been researched along with Body Weight in 133 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (19.55) | 18.7374 |
| 1990's | 9 (6.77) | 18.2507 |
| 2000's | 22 (16.54) | 29.6817 |
| 2010's | 74 (55.64) | 24.3611 |
| 2020's | 2 (1.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bugaj, JE; Dorshow, RB | 2 |
| Alexopoulos, SJ; Beretta, M; Brandon, AE; Byrne, FL; Carrive, P; Chen, SY; Cooney, GJ; Garcia, CJ; Hargett, SR; Hoehn, KL; Lackner, C; Lawrence, RT; Lee, B; Olzomer, EM; Philp, A; Philp, AM; Salamoun, JM; Santos, WL; Shah, DP; Sligar, J; Tucker, SP; Turner, N | 1 |
| Lin, L; Liu, N; Wang, JP; Wang, JQ; Zhang, FK | 1 |
| Bartola, LD; Giampietro, C; Giampietro, O; Masoni, MC; Matteucci, E | 1 |
| Badole, SL; Bagul, PP; Coutinho, EC; Ghule, AE; Jangam, GB; Joshi, AC; Khedkar, VM; Khose, RD; Mahamuni, SP; Raut, CG | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H | 1 |
| Bhargava, A; Del Prato, S; Dharmalingam, M; Garber, AJ; Philis-Tsimikas, A; Rasmussen, S; Satman, I; Skjøth, TV | 1 |
| Caderni, G; Femia, AP; Lodovici, M; Maglieri, G; Mannucci, E; Raimondi, L | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Scheen, AJ | 1 |
| Han, J; Malloy, J; Meloni, A | 1 |
| Du, Q; Liang, YY; Wang, YJ; Wu, B; Yang, S; Zhao, YY | 1 |
| Badole, SL; Bagul, PP; Chaudhari, SM; Joshi, AC; Khose, RD; Mahamuni, SP; Raut, CG; Zanwar, AA | 1 |
| Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C | 1 |
| Chang, G; Duan, Q; Lu, K; Qin, S; Wang, Y; Ye, L; Zhang, D; Zhang, P; Zheng, A | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C | 1 |
| Hardy, E; Jabbour, SA; Parikh, S; Sugg, J | 1 |
| Bi, KS; Chen, XH; Lan, Z | 1 |
| Gallacher, DJ; Hemmeryckx, B; Roger Lijnen, H; Rong Lu, H; Swinnen, M | 1 |
| Cunningham, C; Dey, M; Forest, T; Frederick, C; Holder, D; Prahalada, S; Smith, A; Yao, X | 1 |
| Friedman, TC; Ivey, R; Lee, D; Shin, CS; Sinha-Hikim, AP; Sinha-Hikim, I | 1 |
| Schnell, O | 1 |
| Coric, J; Dizdarevic-Bostandzic, A; Djelilovic-Vranic, J; Izetbegovic, S; Karamehic, J; Macic-Dzankovic, A; Panjeta, M; Velija-Asimi, Z | 1 |
| Carmignac, V; Durbeej, M; Fontes-Oliveira, CC; Holmberg, J; Körner, Z | 1 |
| Funahashi, T; Hayashi, M; Hibuse, T; Hirata, A; Kashine, S; Kimura, T; Kishida, K; Maeda, N; Minami, T; Nakagawa, Y; Nishizawa, H; Oka, A; Shimomura, I; Takeshita, E | 1 |
| Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F | 1 |
| Guthrie, R; Slee, A; Traina, S | 1 |
| Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M | 1 |
| Bae, JY; Baek, LJ; Cheong, HJ; Heo, J; Hwang, MW; Jang, SI; Kim, D; Kim, H; Kim, JI; Lee, I; Lee, S; Park, MS; Park, S; Song, JW; Song, KJ | 1 |
| Baerts, L; Behets, GJ; D'Haese, PC; De Meester, I; Glorie, L; Verhulst, A | 1 |
| Gou, Z; Ma, M; Wang, F; Wang, T; Zhai, SD | 1 |
| Kakehashi, A; Kinoshita, N; Matsumoto, T; Ota, A; Shimmura, M; Takano, H; Tanaka, Y; Toyoda, F; Tsuji, J | 1 |
| Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
| Bailey, RA; Blonde, L; Meininger, GE; Rupnow, MF; Vijapurkar, U | 1 |
| Al-Barazanji, K; Benson, W; Binz, J; Chen, L; Generaux, C; McNulty, J; Young, A | 1 |
| Dai, X; Foretz, M; Liu, J; Liu, Z; Lu, Q; Ouyang, C; Song, P; Viollet, B; Wu, J; Wu, Y; Xie, Z; Yuan, Z; Zhang, W; Zhao, Z; Zhuo, X; Zou, MH | 1 |
| Arndt, K; Budzinski, R; Heckel, A; Kley, JT; Lehmann, T; Lenter, M; Lotz, RR; Maier, GM; Markert, M; Müller, S; Oost, T; Roth, GJ; Rudolf, K; Stenkamp, D; Thomas, L | 1 |
| Cho, DJ; Kim, DW; Kim, SH; Lee, JI; Noh, H; Oh, SJ; Park, HL; Park, MS; Zang, DY | 1 |
| Drucker, DJ; Duez, H; Giacca, A; Lewis, GF; Smith, AC; Szeto, L; Xiao, C | 1 |
| Davidson, JA; Gross, JL; Parente, EB | 1 |
| Al-Husseini, I; Al-Salam, S; Ali, BH; Nemmar, A | 1 |
| Mikhail, N | 2 |
| Liu, Y; Lu, M; Wang, F; Zhang, Y; Zhou, J | 1 |
| Furuta, Y; Julander, JG; Morrey, JD; Smee, DF | 1 |
| Cognard, E; Shepherd, PR; Smith, GC; Vickers, MH | 1 |
| Avezza, F; Canta, A; Carozzi, VA; Cavaletti, G; Ceresa, C; Chiorazzi, A; Crippa, L; Gilardini, A; Marmiroli, P; Meregalli, C; Oggioni, N | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Alexander, CM; Siler, SQ; Topp, BG; Waters, SB | 1 |
| Birnbaum, Y; Keyes, KT; Lin, Y; Perez-Polo, JR; Ye, Y; Zhang, C | 1 |
| Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S | 1 |
| Bilan, VP; Jackson, EK; Tofovic, DS | 1 |
| Davies, MJ; Engel, SS; Mavros, P; Radican, L; Rajagopalan, S; Yin, D; Zhang, Q | 1 |
| Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N | 1 |
| Fernandes, R; Ferreira, L; Garrido, P; Mega, C; Melo, A; Nunes, S; Parada, B; Pinto, F; Pinto, R; Reis, F; Santos, P; Sereno, J; Teixeira, F; Teixeira-de-Lemos, E; Vala, H; Velada, I | 1 |
| Borelli, MI; Del Zotto, H; Flores, LE; Francini, F; Gagliardino, JJ; Madrid, VG; Maiztegui, B; Massa, ML; Raschia, MA; Rebolledo, OR | 1 |
| Bossi, M; Canta, A; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Marmiroli, P; Meregalli, C; Oggioni, N; Sala, B | 1 |
| Coben, J; Dobrian, AD; Galkina, EV; Leone, KA; Lindsay, JW; Ma, K; Ma, Q; Nadler, JL | 1 |
| Anjana, RM; Kishore, U; Mohan, V; Sudhakaran, C; Unnikrishnan, R | 1 |
| Best, JH; Garrison, LP; Li, Y; Malloy, J; Peyrot, M; Rubin, RR; Yan, P | 1 |
| Chen, B; Ernsberger, P; Escobedo, LV; Hou, D; Koletsky, MS; Koletsky, RJ; Moore, A | 1 |
| Liang, Y; Si, LY; Xiao, L; Xu, Q; Yang, QH; Zhang, Y | 1 |
| Cander, S; Ersoy, C; Ertürk, E; Gül, CB; Imamoğlu, S; Kırhan, E; Kıyıcı, S; Öz, Ö; Sarandol, E; Sığırlı, D; Tuncel, E; Ünal, OK; Yorulmaz, H | 1 |
| Böhm, M; Kazakov, A; Laufs, U; Lenski, M; Marx, N | 1 |
| Cho, JH; Ham, DS; Kim, ES; Kim, JW; Park, HS; Sun, C; Yeom, JA; Yoon, KH | 1 |
| de Lemos, ET; Fernandes, R; Mascarenhas-Melo, F; Mega, C; Oliveira, J; Reis, F; Teixeira, F; Vala, H | 1 |
| Holst, JJ; Liu, MK; Salen, G; Saumoy, M; Shang, Q; Xu, G | 1 |
| Auricchio, N; Kwiatkowski, DJ; Malinowska, I; Manning, BD; Shaw, R | 1 |
| Rabasseda, X | 1 |
| Choi, SH; Hong, ES; Jang, HC; Kang, SM; Khang, AR; Lim, S; Park, KS; Shin, H; Walford, GA; Yoon, JW | 1 |
| Ahrén, B; Deacon, CF; Mannucci, E | 1 |
| Cheetham, S; Francis, J; Kirby, M; Poucher, SM; Vickers, SP; Zinker, B | 1 |
| Guo, L; Sun, Y; Wang, A; Xu, C | 1 |
| Burgmaier, M; Esser, M; Liberman, A; Ludwig, A; Marx, N; Ostertag, R; Vasic, D; Vittone, F; Walcher, D | 1 |
| Aschner, P; Chan, J; Dain, MP; Echtay, A; Fonseca, V; Owens, DR; Picard, S; Pilorget, V; Wang, E | 1 |
| Gupta, R; Keshwani, P; Saxena, GN; Srivastava, S | 1 |
| Bailey, T; Davies, M; Filetti, S; Furber, S; Garber, AJ; Montanya, E; Nauck, MA; Pratley, RE; Thomsen, AB | 1 |
| Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H | 1 |
| Aono, M; Fujita, Y; Harashima, SI; Inagaki, N; Koizumi, T; Murata, Y; Ogura, M; Seike, M; Tanaka, D; Wang, Y; Yamane, S | 1 |
| Crajoinas, RO; Fonseca-Alaniz, MH; Giannocco, G; Girardi, AC; Maciel, RM; Oliveira, KC; Salles, TA; Venturini, G | 1 |
| Badole, SL; Bagul, PP; Bodhankar, SL; Coutinho, EC; Ghule, AE; Joshi, AC; Khedkar, VM; Khose, RD; Mahamuni, SP; Raut, CG; Wagh, NK | 1 |
| Arjona Ferreira, JC; Barzilai, N; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Marre, M; Sisk, CM | 1 |
| Kanamori, A; Kubota, A; Maeda, H; Matsuba, I; Tanaka, Y; Terauchi, Y | 1 |
| Lee, LM; Liu, CF; Yang, PP | 1 |
| Cho, MK; Kim, DH; Kim, SG; Kwon, JW; Lee, MG; Yim, YG | 1 |
| Barbera, S; Bigini, P; De Paola, M; Fumagalli, E; Mennini, T | 1 |
| Gao, Y; Guo, P; Li, YF; Liang, QD; Ma, BP; Ma, ZC; Tan, HL; Tan, W; Wang, SQ; Zhou, Z | 1 |
| Bergman, A; Blum, R; Chen, L; Dilzer, S; Herman, GA; Hilliard, D; Lasseter, K; Liu, F; Meehan, AG; Snyder, K; Stevens, C; Tanaka, W; Tanen, M; Wagner, JA; Wang, AQ; Zeng, W | 1 |
| Ahrén, B | 3 |
| Alba, M; Amatruda, JM; Chen, Y; Hussain, S; Kaufman, KD; Langdon, RB; Raz, I; Stein, PP; Wu, M | 1 |
| Davies, MJ; Engel, SS; Loeys, T; Scott, R | 1 |
| Stastná, J; Tousek, J; Viklický, J; Zítková, L | 1 |
| Eastell, R; Edmonds, CJ | 1 |
| Cameron, IL; Pool, TB; Smith, NK; Sparks, RL | 1 |
| Drayer, JI; Hoefnagels, WH; Kloppenborg, PW; Smals, AG | 1 |
| Baron, JH; Gribble, RJ; Holdstock, DJ; Lewis, SI; Murgatroyd, RE; Reed, PI; Vincent-Brown, A | 1 |
| Olesen, OV; Thomsen, K | 1 |
| Grimshaw, JJ; Jaffé, G; Vallé-Jones, JC; Warnock, JM | 1 |
| Antelman, SM; Kocan, D; Rowland, N | 1 |
| Alcazar, JM; Diaz, VP; Jarillo, MD; Millet, VG; Rodicio, JL; Ruilope, L | 1 |
| Clapper, ML; Lang, D; Leahy, K; Miknyoczki, S; Ruggeri, BA; Wood, M | 1 |
| Hermann, M; Hromadová, M; Klimes, I; Minchenko, A; Mitková, A; Seböková, E | 1 |
| Jemiolo, B; Novotny, M | 1 |
| Kensler, TW; MacMillan, DL; Maxuitenko, YY; Roebuck, BD | 1 |
| Ahmed, SA; Gad, MZ | 1 |
| Kelloff, G; Rao, CV; Reddy, BS; Rivenson, A; Steele, V; Zang, E | 1 |
| Crowell, JA; Goldenthal, EI; Hall, LB; Heath, JE; Kelloff, GJ; Page, JG; Rodman, LE | 1 |
| Barnea, A; Gvaryahu, G; Katz, A; Robinzon, B; Snapir, N | 1 |
| Furukawa, F; Hirose, M; Ikeda, T; Kasahara, KI; Miyauchi, M; Nakamura, H; Nishikawa, A; Son, HY | 1 |
| Arif, JM; Gupta, RC; Smith, WA | 1 |
| Ahn, B; Choi, KS; Kang, JS; Kim, DJ; Kim, KS; Kim, ND; Park, KH; Surh, YJ | 1 |
| Bonaduce, D; D'Ascia, C; Ferrara, N; Petretta, M; Rengo, F; Saccá, L; Trimarco, B | 1 |
| Mikkelsen, E; Pedersen, OL | 1 |
| Antcliff, AC; Beevers, DG; Hamilton, M; Pearce, VR | 1 |
| Dufour, JJ; Posternak, JM; Rogg, C; Vodoz, CA | 1 |
| Nayini, J; Rao, CV; Reddy, BS | 1 |
| Itoh, R; Ohta, A; Yamada, K | 1 |
| Groopman, JD; Kensler, TW; Liu, YL; Roebuck, BD; Yager, JD | 1 |
| Larochelle, P; Logan, AG | 1 |
| Alon, U; Chan, JC | 1 |
| Bühring, KU; Leopold, G; Pabst, J; Simane, Z; Ungethüm, W | 1 |
| Breckenridge, AM; Dollery, CT; George, CF | 1 |
| Nash, DT | 1 |
| Fagerberg, SE; Johannessen, A | 1 |
| Hohenegger, M | 1 |
| Goulding, A; Irvine, RO; Jukes, C | 1 |
| Irvine, RO; McKean, WI | 1 |
| Jelinek, J; Krajny, M; Selye, H | 1 |
| McNay, JL; Oran, E | 1 |
13 review(s) available for pyrazines and Body Weight
| Article | Year |
|---|---|
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Topics: Adamantane; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular System; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Lipids; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis.
Topics: Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult | 2014 |
Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.
Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Lipids; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2010 |
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin | 2010 |
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Male; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2012 |
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting | 2008 |
31 trial(s) available for pyrazines and Body Weight
| Article | Year |
|---|---|
Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.
Topics: Administration, Oral; Argentina; Blood Glucose; Body Weight; Canada; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; India; Insulin, Long-Acting; Male; Mexico; Middle Aged; Pyrazines; Sitagliptin Phosphate; South Africa; Treatment Outcome; Triazoles; Turkey; United States | 2013 |
Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Topics: Blood Glucose; Body Weight; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss | 2014 |
The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides | 2013 |
A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study.
Topics: Adiponectin; Aged; Asian People; Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2014 |
The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
Topics: Adult; Age Factors; Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Behavior; Humans; Hypoglycemic Agents; Male; Middle Aged; Personal Satisfaction; Pyrazines; Quality of Life; Self Efficacy; Sex Factors; Sexual Behavior; Sitagliptin Phosphate; Thiophenes; Triazoles; Weight Loss | 2014 |
Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin.
Topics: Adult; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2014 |
Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
Topics: Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2014 |
Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Body Surface Area; Body Weight; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome; Young Adult | 2016 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Resistin; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Tumor Necrosis Factor-alpha | 2010 |
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Female; Health Status; Humans; Hypoglycemic Agents; Male; Mental Health; Middle Aged; Patient Satisfaction; Peptides; Pioglitazone; Pyrazines; Quality of Life; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes.
Topics: Aged; Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Female; Ghrelin; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Turkey | 2011 |
Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Waist Circumference | 2012 |
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Triazoles | 2012 |
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Liraglutide; Metformin; Nausea; Patient Satisfaction; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients.
Topics: Aged; Asian People; Body Mass Index; Body Weight; C-Peptide; Demography; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Pyrazines; ROC Curve; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Pyrazines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles | 2013 |
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Administration, Oral; Blood Glucose; Body Weight; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycoproteins; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Triglycerides | 2008 |
The influence of amiloride on the therapeutic and metabolic effects of carbenoxolone in patients with gastric ulcer. A double-blind controlled trial.
Topics: Adult; Amiloride; Blood Pressure; Body Weight; Carbenoxolone; Clinical Trials as Topic; Double-Blind Method; Female; Glycyrrhetinic Acid; Humans; Male; Middle Aged; Pyrazines; Random Allocation; Stomach Ulcer | 1980 |
Individual factors influencing the response to a beta-adrenergic blocking agent given alone and in combination with a diuretic on arterial hypertension.
Topics: Adult; Aging; Amiloride; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Propanolamines; Pyrazines; Time Factors; Timolol | 1979 |
Hydrochlorothiazide-amiloride versus hydrochlorothiazide alone for essential hypertension: effects on blood pressure and serum potassium level.
Topics: Adolescent; Adult; Age Factors; Aged; Amiloride; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Potassium; Pulse; Pyrazines; Random Allocation | 1985 |
[Esmaloride--a new potassium neutral diuretic combination. Clinical pharmacologic properties].
Topics: Aldosterone; Amiloride; Blood Glucose; Blood Pressure; Body Weight; Creatinine; Drug Combinations; Female; Heart Rate; Humans; Hypertension; Male; Potassium; Pyrazines; Trichlormethiazide; Triglycerides; Uric Acid; Water-Electrolyte Balance | 1985 |
Comparison of the potassium- retaining effects of amiloride and spironolactone in hypertensive patients with thiazide-induced hypokalaemia.
Topics: Adult; Aged; Amiloride; Blood Pressure; Body Weight; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Male; Middle Aged; Pyrazines; Sodium; Spironolactone; Time Factors; Urea | 1973 |
Glipizide, a new oral antidiabetic agent (report of a controlled clinical study in Sweden).
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus; Diet, Diabetic; Drug Evaluation; Female; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Potassium; Pyrazines; Sodium; Sulfonylurea Compounds; Sweden; Time Factors | 1973 |
89 other study(ies) available for pyrazines and Body Weight
| Article | Year |
|---|---|
Absence of developmental or reproductive toxicity in rats for MB-102, a fluorescent tracer agent for point-of-care measurement of glomerular filtration rate.
Topics: Animals; Body Weight; Cesarean Section; Coloring Agents; Dogs; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Point-of-Care Systems; Pregnancy; Pyrazines; Rabbits; Rats; Reproduction | 2022 |
Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice.
Topics: Adipose Tissue; Administration, Oral; Animals; Blood Glucose; Body Temperature; Body Weight; Diamines; Diet, Western; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose Clamp Technique; Humans; Insulin Resistance; Liver; Male; Membrane Potential, Mitochondrial; Mice; Mitochondria; Obesity; Oxadiazoles; Oxidative Stress; Pyrazines | 2020 |
Tetramethylpyrazine supplementation reduced Salmonella Typhimurium load and inflammatory response in broilers.
Topics: Animal Feed; Animals; Body Weight; Chickens; Diet; Gastrointestinal Contents; Inflammation; Male; Permeability; Poultry Diseases; Pyrazines; Salmonella Infections, Animal; Salmonella typhimurium | 2019 |
Oral L-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Colon; Diabetes Mellitus, Experimental; Drinking; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Glutamine; Glycated Hemoglobin; Insulin; Lipid Metabolism; Male; Molecular Docking Simulation; Niacinamide; Oxidative Stress; Pancreas; Peptide Fragments; Protein Conformation; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles | 2013 |
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiotonic Agents; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart; Heart Rate; Insulin; Insulin Resistance; Male; Malondialdehyde; Membrane Potential, Mitochondrial; Mitochondria, Heart; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats.
Topics: 1,2-Dimethylhydrazine; Animals; Body Weight; Carcinogenesis; Colonic Neoplasms; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Intestinal Mucosa; Intestines; Male; Mucins; Pyrazines; Random Allocation; Rats; Rats, Inbred F344; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles | 2013 |
Effect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7-36) amide secretion, biochemical and oxidative stress in streptozotocin - nicotinamide induced diabetic Sprague Dawley rats.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Colon; Diabetes Mellitus, Experimental; Drinking Behavior; Feeding Behavior; Glucagon-Like Peptide 1; Glutamine; Glycated Hemoglobin; Insulin; Lipid Metabolism; Male; Niacinamide; Oxidative Stress; Pancreas; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Staining and Labeling; Streptozocin; Triazoles; Triterpenes | 2013 |
Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model.
Topics: Animals; Apoptosis; Body Weight; Cardiotonic Agents; Creatine Kinase, MB Form; Disease Models, Animal; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glutathione Peroxidase; Heart; Heart Ventricles; L-Lactate Dehydrogenase; Male; Malondialdehyde; Myocytes, Cardiac; Organ Size; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Reperfusion Injury; Sitagliptin Phosphate; Superoxide Dismutase; Triazoles | 2013 |
Ligustrazine attenuates elevated levels of indoxyl sulfate, kidney injury molecule-1 and clusterin in rats exposed to cadmium.
Topics: Animals; Body Weight; Cadmium; Cell Adhesion Molecules; Clusterin; Indican; Kidney; Male; Pyrazines; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2014 |
Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diet, High-Fat; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Heart; Heart Function Tests; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Myocardium; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Keratins; Ki-67 Antigen; Male; Metformin; Pancreas, Exocrine; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles | 2014 |
Nicotine in combination with a high-fat diet causes intramyocellular mitochondrial abnormalities in male mice.
Topics: Acetyl-CoA Carboxylase; Adipose Tissue; Animals; Body Weight; Diet, High-Fat; Fatty Acids, Nonesterified; Lipolysis; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Mitochondria; Muscle Fibers, Skeletal; Muscle, Skeletal; Nicotine; Obesity; Oxidative Stress; Pyrazines; Risk Factors; Smoking; Triglycerides | 2014 |
Bortezomib partially improves laminin α2 chain-deficient muscular dystrophy.
Topics: Animals; Apoptosis; Body Weight; Boronic Acids; Bortezomib; Cells, Cultured; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Laminin; Locomotion; Mice, Inbred C57BL; MicroRNAs; Muscle Cells; Muscles; Muscular Dystrophy, Animal; Organ Specificity; Proteasome Endopeptidase Complex; Pyrazines; Survival Analysis | 2014 |
Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Body Weight; Cyclopentanes; Dogs; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Female; Guanidines; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred DBA; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Survival Rate | 2014 |
DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
Topics: Animals; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Compressive Strength; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Male; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Streptozocin; Stress, Mechanical; Triazoles | 2014 |
Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
Topics: Administration, Oral; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetic Retinopathy; Disease Models, Animal; Drug Administration Schedule; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Glycated Hemoglobin; Male; Neuroprotective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; Retina; Rhodanine; Spiro Compounds; Thiazolidines; Time Factors | 2014 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
Pre-clinical toxicity evaluation of MB-102, a novel fluorescent tracer agent for real-time measurement of glomerular filtration rate.
Topics: Animals; Body Weight; Coloring Agents; Dogs; Female; Fluorescent Dyes; Glomerular Filtration Rate; Humans; Male; Pyrazines; Rats; Rats, Sprague-Dawley; Toxicity Tests | 2015 |
Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice.
Topics: Animals; Body Weight; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Synergism; Eating; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oxadiazoles; Proto-Oncogene Proteins c-fos; Pyrazines; Receptors, G-Protein-Coupled; Weight Loss | 2015 |
Activation of AMPKα2 in adipocytes is essential for nicotine-induced insulin resistance in vivo.
Topics: Adipocytes; Adiposity; AMP-Activated Protein Kinases; Animals; Body Composition; Body Weight; Dual Specificity Phosphatase 1; Enzyme Activation; HEK293 Cells; Homeostasis; Humans; Hypolipidemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Phosphorylation; Pyrazines; Rats; Serine; Smoking | 2015 |
Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Drug Discovery; Ether-A-Go-Go Potassium Channels; Hepatocytes; High-Throughput Screening Assays; Humans; In Vitro Techniques; Lipidoses; Microsomes, Liver; Phospholipids; Potassium Channel Blockers; Pyrazines; Pyridazines; Pyridines; Rats; Receptors, Somatostatin; Structure-Activity Relationship | 2015 |
Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
Topics: Animals; Blood Glucose; Body Weight; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucose Clamp Technique; Glucose Tolerance Test; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred C57BL; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Comparative protective effect of N-acetyl cysteine and tetramethylpyrazine in rats with gentamicin nephrotoxicity.
Topics: Acetylcysteine; Acute Kidney Injury; Animals; Antioxidants; Body Weight; Creatinine; Gentamicins; Kidney Cortex; Male; Protective Agents; Protein Synthesis Inhibitors; Pyrazines; Rats; Rats, Wistar; Urea; Urodynamics | 2009 |
[Effect of tetramethylpyrazine on expression of Smad7 and SnoN in rats with UUO].
Topics: Animals; Body Weight; Collagen; Gene Expression Regulation; Kidney; Male; Nerve Tissue Proteins; Peptide Fragments; Procollagen; Pyrazines; Rats; Smad7 Protein; Transcription Factors; Transforming Growth Factor beta; Ureteral Obstruction | 2009 |
Effect of T-705 treatment on western equine encephalitis in a mouse model.
Topics: Administration, Oral; Amides; Animals; Antiviral Agents; Body Weight; Chlorocebus aethiops; Disease Models, Animal; Encephalomyelitis, Western Equine; Mice; Mice, Inbred C57BL; Pyrazines; Serum; Survival Analysis; Vero Cells | 2009 |
Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Body Composition; Body Weight; Clozapine; Dibenzothiazepines; Dietary Fats; Disease Models, Animal; Eating; Exenatide; Food Preferences; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Peptides; Pyrazines; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Blood Cell Count; Blood Chemical Analysis; Body Weight; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Hot Temperature; Neural Conduction; Neurotoxicity Syndromes; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve | 2010 |
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Metformin; Models, Theoretical; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.
Topics: Animals; Blood Glucose; Blotting, Western; Body Weight; Culture Media; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl-Peptidase IV Inhibitors; Eicosanoids; Glucagon-Like Peptide 1; Hypertrophy, Left Ventricular; Hypoglycemic Agents; In Vitro Techniques; Mice; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Organ Size; Phospholipases A2; Pioglitazone; Prostaglandin-Endoperoxide Synthases; Protective Agents; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2010 |
Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.
Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Hypertension; Kidney; Male; Metabolic Syndrome; Proteinuria; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Sitagliptin Phosphate; Triazoles; Vasoconstriction; Vasoconstrictor Agents | 2010 |
Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
Topics: Adult; Age Factors; Aged; Body Mass Index; Body Weight; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insurance Claim Review; Lipids; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sex Factors; Sitagliptin Phosphate; Socioeconomic Factors; Triazoles; Venoms | 2010 |
Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glycated Hemoglobin; Insulin; Insulin Resistance; Interleukin-1beta; Lipids; Male; Oxidative Stress; Pancreas; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2010 |
Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Diet; Dipeptidyl-Peptidase IV Inhibitors; Drinking; Drug Evaluation, Preclinical; Eating; Exenatide; Fatty Liver; Fructose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metabolic Syndrome; Peptides; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Body Weight; Boronic Acids; Bortezomib; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Ganglia, Spinal; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nerve Fibers, Myelinated; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Sciatic Nerve | 2010 |
[New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles | 2010 |
Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
Topics: Adipocytes; Adipose Tissue; Adiposity; Animals; Anti-Inflammatory Agents; Body Weight; Cytokines; Dipeptidyl-Peptidase IV Inhibitors; Flow Cytometry; Glucose; Glucose Intolerance; Glucose Tolerance Test; Immunohistochemistry; Inflammation; Insulin; Islets of Langerhans; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Neutrophil Infiltration; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles | 2011 |
Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; India; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Statistics, Nonparametric; Triazoles; Triglycerides | 2011 |
Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Feeding Behavior; Glucagon; Glucagon-Like Peptide 1; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2011 |
Protective effect of tetramethylpyrazine isolated from Ligusticum chuanxiong on nephropathy in rats with streptozotocin-induced diabetes.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Ligusticum; Male; Phytotherapy; Plant Extracts; Protective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Endothelial Growth Factor A | 2011 |
Effects of DPP-4 inhibition on cardiac metabolism and function in mice.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Body Weight; CD36 Antigens; Cell Membrane; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fibrosis; Glucose Tolerance Test; Glucose Transporter Type 4; Glycation End Products, Advanced; Guanine; Heart; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Phosphorylation; Protein Transport; Pyrazines; Sitagliptin Phosphate; Triazoles; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2011 |
Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Fasting; Glucose Tolerance Test; Homeostasis; Insulin-Secreting Cells; Ki-67 Antigen; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Organ Size; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2011 |
Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Insulin; Kidney Glomerulus; Lipid Peroxidation; Lipids; Male; Obesity; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2011 |
The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
Topics: Allylamine; Animals; Anticholesteremic Agents; Apoptosis; Bile Acids and Salts; Blood Glucose; Body Weight; Cell Proliferation; Cell Size; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Diet; Drug Synergism; Fluorescent Antibody Technique; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; In Situ Nick-End Labeling; Insulin; Insulin-Secreting Cells; Ki-67 Antigen; Male; Postprandial Period; Pyrazines; Rats; Rats, Zucker; Receptors, G-Protein-Coupled; RNA, Messenger; Sitagliptin Phosphate; Triazoles | 2012 |
Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC).
Topics: Animals; Body Weight; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Immunoblotting; Immunohistochemistry; Kidney Diseases, Cystic; Kidney Neoplasms; Metformin; Mice; Pyrazines; Treatment Outcome; Tuberous Sclerosis | 2012 |
[Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].
Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptides; Drinking; Eating; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Immunohistochemistry; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Evaluation of antioxidant and immunity function of tetramethylpyrazine phosphate tablets in vivo.
Topics: Animals; Antioxidants; Blood Pressure; Body Weight; Cardiotonic Agents; Catalase; Glutathione Peroxidase; Heart; Heart Failure; Interleukin-6; Isoproterenol; Malondialdehyde; Organ Size; Organophosphates; Oxidative Stress; Pyrazines; Rats; Rats, Wistar; Superoxide Dismutase; Tablets; Tumor Necrosis Factor-alpha; Ventricular Function, Left | 2012 |
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Immunohistochemistry; Lipid Metabolism; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
Topics: Adult; Alanine Transaminase; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Drug Evaluation; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Inflammation; Liraglutide; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Odds Ratio; Pioglitazone; Platelet Count; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2012 |
Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose; Glucose Transporter Type 4; Heart; Homeostasis; Intracellular Space; Male; Muscle, Skeletal; Myocytes, Cardiac; Phosphorylation; Protein Transport; Pyrazines; Rats; Rats, Inbred SHR; RNA, Messenger; Signal Transduction; Sitagliptin Phosphate; Triazoles; Up-Regulation | 2013 |
Cycloart-23-ene-3β, 25-diol stimulates GLP-1 (7-36) amide secretion in streptozotocin-nicotinamide induced diabetic Sprague Dawley rats: a mechanistic approach.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drinking; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucose Tolerance Test; Insulin; Male; Molecular Docking Simulation; Niacinamide; Oxidative Stress; Pancreas; Peptide Fragments; Protein Conformation; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Time Factors; Triazoles; Triterpenes | 2013 |
Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Effect of tetramethylpyrazine on lipid peroxidation in streptozotocin-induced diabetic mice.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Diabetes Mellitus, Experimental; Free Radical Scavengers; Lipid Peroxidation; Male; Malondialdehyde; Mice; Mice, Inbred ICR; Pyrazines; Thiobarbituric Acid Reactive Substances | 2002 |
Effects of cysteine on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agent, in rats with protein-calorie malnutrition.
Topics: Animals; Body Weight; Chromatography, High Pressure Liquid; Cysteine; Eating; Injections, Intravenous; Male; Organ Size; Protective Agents; Protein-Energy Malnutrition; Pyrazines; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2003 |
Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease.
Topics: Animals; Body Weight; Brain-Derived Neurotrophic Factor; CD11b Antigen; Cell Death; Choline O-Acetyltransferase; Disease Models, Animal; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Imidazoles; Immunohistochemistry; Mice; Mice, Neurologic Mutants; Motor Activity; Motor Neurons; Neurodegenerative Diseases; Psychomotor Performance; Pyrazines; Radioimmunoassay; Riluzole | 2006 |
Effects of four Si-Wu-Tang's constituents and their combination on irradiated mice.
Topics: Animals; Benzoates; Body Weight; Bone Marrow Cells; Bridged-Ring Compounds; Colony-Forming Units Assay; Coumaric Acids; Disease Models, Animal; Dose-Response Relationship, Radiation; Drugs, Chinese Herbal; Female; Fructose; Gamma Rays; Glucosides; Hematopoietic Stem Cells; Mice; Mice, Inbred C57BL; Monoterpenes; Pyrazines; Radiation-Protective Agents; Stem Cells; Thymus Gland | 2006 |
Toxicity of morphazinamide compared with pyrazinamide.
Topics: Animals; Blood Chemical Analysis; Body Weight; Eating; Liver; Male; Pyrazinamide; Pyrazines; Rats; Rats, Inbred Strains | 1983 |
Hyponatraemia associated with trimethoprim and a diuretic.
Topics: Aged; Amiloride; Body Weight; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hyponatremia; Pyrazines; Trimethoprim; Urinary Tract Infections; Urodynamics | 1984 |
Effects of amiloride on tumor growth and intracellular element content of tumor cells in vivo.
Topics: Adenocarcinoma; Amiloride; Animals; Body Weight; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Liver Neoplasms, Experimental; Male; Mice; Pyrazines; Sodium | 1983 |
Spironolactone and amiloride in hypertensive patients with and without aldosterone excess.
Topics: Adult; Amiloride; Blood Pressure; Body Weight; Female; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged; Potassium; Pyrazines; Renin; Spironolactone; Urea | 1980 |
A comparison between the natriuretic response to potassium in lithium- and amiloride-treated rats.
Topics: Amiloride; Animals; Body Weight; Dose-Response Relationship, Drug; Drinking; Lithium; Male; Natriuresis; Potassium; Pyrazines; Rats; Rats, Inbred Strains; Renin; Sodium; Time Factors | 1981 |
A comparative study of Moducren and Moduretic and their effect on plasma potassium in essential hypertension.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Body Weight; Drug Combinations; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Potassium; Propanolamines; Pyrazines; Random Allocation; Timolol | 1982 |
Differences among 'serotonergic' anorectics in a cross-tolerance paradigm: do they all act on serotonin systems?
Topics: Animals; Appetite Depressants; Body Weight; Drug Tolerance; Fenfluramine; Male; Pyrazines; Quipazine; Rats; Rats, Inbred Strains; Receptors, Serotonin | 1982 |
A fixed combination of hydrochlorothiazide and amiloride for the treatment of essential hypertension.
Topics: Adolescent; Adult; Aged; Amiloride; Blood Chemical Analysis; Blood Pressure; Body Weight; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Hydrochlorothiazide; Hyperglycemia; Hypertension; Male; Middle Aged; Pyrazines; Uric Acid | 1980 |
Chemopreventive activity of Oltipraz against N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters.
Topics: Animals; Anticarcinogenic Agents; Body Weight; Carcinogens; Carcinoma, Ductal, Breast; Cricetinae; Female; Glutathione Transferase; Immunohistochemistry; Liver; Mesocricetus; Nitrosamines; Pancreas; Pancreatic Neoplasms; Pyrazines; Thiones; Thiophenes; Tumor Suppressor Protein p53 | 1995 |
Modulation of the hypolipidemic effect of fish oil by inhibition of adipose tissue lipolysis with acipimox, a nicotinic acid analog.
Topics: Acetyl-CoA Carboxylase; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Dietary Fats, Unsaturated; Eating; Fatty Acids, Nonesterified; Fish Oils; Insulin; Lipids; Lipolysis; Liver; Male; Pyrazines; Rats; Rats, Wistar; Receptors, LDL; Sucrose; Triglycerides | 1993 |
Inhibition of sexual maturation in juvenile female and male mice by a chemosignal of female origin.
Topics: Animals; Body Weight; Female; Male; Mice; Mice, Inbred ICR; Organ Size; Pregnancy; Pyrazines; Seminal Vesicles; Sex Attractants; Sexual Maturation; Smell; Social Environment; Testis | 1994 |
Evaluation of the post-initiation effects of oltipraz on aflatoxin B1-induced preneoplastic foci in a rat model of hepatic tumorigenesis.
Topics: Aflatoxin B1; Animals; Anticarcinogenic Agents; Body Weight; Glutathione Transferase; Liver; Liver Neoplasms, Experimental; Male; Organ Size; Precancerous Conditions; Pyrazines; Rats; Rats, Inbred F344; Thiones; Thiophenes; Time Factors | 1993 |
Effect of schistosomal infection and its treatment on some key enzymes of glucose metabolism in mice livers.
Topics: Animals; Body Weight; Citric Acid Cycle; Female; Glucose; Glycolysis; Liver; Liver Glycogen; Male; Mice; Organ Size; Oxamniquine; Pentose Phosphate Pathway; Praziquantel; Pyrazines; Schistosomiasis mansoni; Schistosomicides; Thiones; Thiophenes | 1995 |
Inhibition of 2-Amino-1-methyl-6-phenylimidazo[4,5]pyridine-induced lymphoma formation by oltipraz.
Topics: Animals; Anticarcinogenic Agents; Body Weight; Carcinogens; Imidazoles; Intestinal Neoplasms; Lymphoma; Male; Pyrazines; Rats; Rats, Inbred F344; Thiones; Thiophenes | 1996 |
Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, a potential chemopreventive agent.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Anticarcinogenic Agents; Blood Chemical Analysis; Body Weight; Cholesterol; Dogs; Female; Hematologic Tests; Kidney; Liver; Male; No-Observed-Adverse-Effect Level; Organ Size; Prostate; Pyrazines; Rats; Rats, Inbred F344; Survival Rate; Thiones; Thiophenes | 1997 |
The effect of pyrazine odor on body weight and the weight of various organs in chicks (Gallus gallus domesticus).
Topics: Adipose Tissue; Adrenal Glands; Animals; Body Weight; Bursa of Fabricius; Chick Embryo; Chickens; Comb and Wattles; Female; Liver; Male; Odorants; Organ Size; Ovary; Pyrazines; Sex Characteristics; Spleen; Thyroid Gland; Time Factors | 1999 |
Organ-dependent modifying effects of oltipraz on N-nitrosobis(2-oxopropyl)amine (BOP)-initiation of tumorigenesis in hamsters.
Topics: Animals; Anticarcinogenic Agents; Body Weight; Carcinogens; Cell Transformation, Neoplastic; Cricetinae; Female; Mesocricetus; Neoplasms, Experimental; Nitrosamines; Organ Size; Pyrazines; Thiones; Thiophenes | 2000 |
1,2-dithiole-3-thione and its structural analogue oltipraz are potent inhibitors of dibenz.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Benzopyrenes; Body Weight; Chromatography; DNA Adducts; Female; Liver; Lung; Mammary Glands, Animal; Pyrazines; Rats; Rats, Sprague-Dawley; Thiones; Thiophenes | 2001 |
Chemopreventive effect of 2-(allylthio)pyrazine (2-AP) on rat colon carcinogenesis induced by azoxymethane (AOM).
Topics: Animals; Azoxymethane; Body Weight; Carcinogens; Colon; Colonic Neoplasms; Enzyme Inhibitors; Intestinal Mucosa; Male; Organ Size; Pyrazines; Rats; Rats, Inbred F344 | 2001 |
Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Fatty Acids, Nonesterified; Female; Glucose Intolerance; Glucose Tolerance Test; Hypolipidemic Agents; Injections, Intraperitoneal; Insulin; Mice; Mice, Inbred C57BL; Pyrazines | 2001 |
Potassium sparing effect of amiloride in patients receiving diuretics: a quantitative study.
Topics: Adult; Amiloride; Body Weight; Diuretics; Female; Humans; Hydrochlorothiazide; Male; Middle Aged; Potassium; Pyrazines; Sodium; Time Factors | 1979 |
Total exchangeable potassium in response to amiloride.
Topics: Amiloride; Body Weight; Carbon Dioxide; Humans; Hypertension; Hypokalemia; Potassium; Pyrazines; Time Factors | 1978 |
Toxicological tests on flavouring matters. II. Pyrazines and other compounds.
Topics: Animals; Body Weight; Diet; Female; Kidney; Liver; Male; Organ Size; Pyrazines; Rats; Rats, Inbred Strains | 1975 |
Effect of oltipraz [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] on azoxymethane-induced biochemical changes related to early colon carcinogenesis in male F344 rats.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Body Weight; Colon; Colonic Neoplasms; Cytosol; DNA; Glutathione Transferase; Intestinal Mucosa; Liver; Male; Methylation; Ornithine Decarboxylase; Protein-Tyrosine Kinases; Pyrazines; Rats; Rats, Inbred F344; Reference Values; Thiones; Thiophenes | 1991 |
Influence of pyrazine derivatives on the day of vaginal opening in juvenile female rats.
Topics: Animals; Body Weight; Female; Organ Size; Ovary; Pyrazines; Rats; Rats, Inbred Strains; Uterus; Vagina | 1989 |
Protection by 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) against the hepatotoxicity of aflatoxin B1 in the rat.
Topics: Aflatoxin B1; Aflatoxins; Animals; Body Weight; Butylated Hydroxytoluene; DNA; Enzyme Induction; Glutathione Transferase; Liver; Male; Pyrazines; Rats; Rats, Inbred F344; Thiones; Thiophenes | 1988 |
Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus.
Topics: Adult; Alkalosis; Amiloride; Body Weight; Child; Diabetes Insipidus; Drug Therapy, Combination; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypokalemia; Kidney Tubules; Male; Pyrazines; Tolmetin | 1985 |
A clinical study of Co-hydroDiuril a combination of an antikaliuretic (amiloride) and hydrochlorothiazide.
Topics: Adult; Aged; Amiloride; Blood Pressure; Blood Urea Nitrogen; Body Weight; Diuretics; Drug Combinations; Drug Eruptions; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Potassium; Pyrazines; Urinary Incontinence; Vertigo | 1972 |
Potassium-escape phenomenon in rats during continuous application of amiloride. IV. Etiology of the escape phenomenon.
Topics: Amiloride; Animals; Body Weight; Diet; Diuretics; Feces; Male; Potassium; Pyrazines; Rats | 1973 |
Effects of hydrochlorothiazide and amiloride on potassium distribution in skeletal muscle of the rat.
Topics: Amiloride; Animals; Body Weight; Chlorides; Diuretics; Extracellular Space; Hydrochlorothiazide; Male; Muscles; Potassium; Pyrazines; Rats; Sodium; Water | 1973 |
Evaluation of amiloride combined with hydrochlorothiazide in the treatment of congestive heart failure.
Topics: Aged; Amidines; Body Weight; Diuretics; Drug Synergism; Female; Heart Failure; Humans; Hydrochlorothiazide; Male; Middle Aged; Potassium; Pyrazines; Sodium; Time Factors; Urea | 1970 |
Prevention of digitoxin poisoning by various steroids.
Topics: Anabolic Agents; Androstanes; Animals; Body Weight; Desoxycorticosterone; Digitoxin; Diuretics; Estradiol; Ethisterone; Ethylestrenol; Female; Fluoxymesterone; Hydrocortisone; Ketones; Methyltestosterone; Nandrolone; Norethandrolone; Norethynodrel; Organ Size; Oxandrolone; Oxymetholone; Poisoning; Pregnanes; Pregnenolone; Progesterone; Pyrazines; Rats; Spironolactone; Testosterone; Triamterene | 1969 |
Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870).
Topics: Adult; Aged; Bicarbonates; Blood Pressure; Body Weight; Chemical Phenomena; Chemistry; Chlorides; Creatinine; Diabetes Mellitus; Diuretics; Electrocardiography; Female; Humans; Hyperkalemia; Male; Middle Aged; Potassium; Pyrazines; Sodium; Spironolactone; Triamterene; Water-Electrolyte Balance | 1970 |